DATA GRAPHICS | Data Byte
Rising popularity of CVRs in biopharma M&A
By bridging valuation gaps, CVRs have become an increasingly key tool for getting acquisitions done
July 22, 2023 12:51 AM UTC
Contingent value rights (CVRs) are becoming increasingly popular in biopharma M&A, particularly for small- and mid-cap acquisitions this year.
As of July 20, 15 acquisitions that include a CVR had been announced this year, more than the total of 13 such deals in the entire previous year. Investors who spoke to BioCentury for its 3Q23 Financial Markets Preview anticipate increased M&A in the second half, and greater use of CVRs could certainly help make that prediction a reality...